Articles related to OFF-LABEL USE

To sum up the reasons you should use caution: Quetiapine has a variety of effects, including sedation, influencing a number of central nervous system receptors. Quetiapine should only be used to treat insomnia in patients who also have co-occurring mood or schizophrenia spectrum disorders. Quetiapine is less frequently linked to extrapyramidal side effects and dystonia than many other antipsychotic medications, but it is more frequently linked to weight gain, metabolic syndrome, and QTc prolongation. Prior to beginning treatment and then on a frequent basis thereafter, measurements of body mass index, weight, blood pressure, fasting glucose, and lipid levels should be made, even at modest doses. Despite not producing euphoria, quetiapine is frequently misused to amplify or lessen the negative effects of illegal substances. For older patients, quetiapine has additional dangers.

Because this GLP-1 agonist is known to reduce food intake, physicians have been prescribing tirzepatide off-label for weight loss for years. But unlike other drugs in its class, tirzepatide targets GLP-1 and GIP receptors.

Despite having anti-psychotic, anxiolytic, sedative, and hypnotic properties, quetiapine is linked to an increased risk of cardiovascular death and sudden cardiac death when used in conventional doses. For the first time, the current investigation demonstrated that quetiapine taken off-label and in modest doses raises the risk of major adverse cardiovascular events (MACE), stroke, and cardiovascular death.